Citi analyst Graham Parry initiated coverage of Novartis (NVS) with a Buy rating and CHF 133 price target The firm sees the company’s earnings outperformance continuing. It believes Novartis will hit its 5%-6% annual sales growth guidance through 2030.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- AI Daily: Nvidia invests $2B in CoreWeave
- Drugmakers use AI to help progress through trials, submissions, Reuters says
- Amgen downgraded to Market Perform from Outperform at Bernstein
- Trump Trade: Trump announces tariffs on NATO countries over Greenland
- Novartis Stock (NVS) Holds on Upbeat View of Tariff Exposure amid U.S.-EU Tension